BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRNGet Rating) have received a consensus recommendation of “Moderate Buy” from the seventeen analysts that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $112.86.

BMRN has been the topic of several recent research reports. Credit Suisse Group increased their price objective on shares of BioMarin Pharmaceutical to $111.00 in a research note on Tuesday, August 9th. Piper Sandler increased their price objective on shares of BioMarin Pharmaceutical from $125.00 to $128.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 9th. Barclays increased their price objective on shares of BioMarin Pharmaceutical from $112.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, August 4th. SVB Leerink increased their price objective on shares of BioMarin Pharmaceutical from $115.00 to $122.00 and gave the stock an “outperform” rating in a research note on Thursday, August 4th. Finally, TheStreet upgraded shares of BioMarin Pharmaceutical from a “c+” rating to a “b-” rating in a research note on Friday, September 9th.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Jeffrey Robert Ajer sold 3,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $95.62, for a total value of $286,860.00. Following the completion of the transaction, the executive vice president now directly owns 44,088 shares of the company’s stock, valued at $4,215,694.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Jean Jacques Bienaime sold 4,000 shares of the firm’s stock in a transaction on Friday, August 12th. The shares were sold at an average price of $94.75, for a total value of $379,000.00. Following the completion of the transaction, the chief executive officer now directly owns 331,324 shares of the company’s stock, valued at $31,392,949. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Jeffrey Robert Ajer sold 3,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $95.62, for a total transaction of $286,860.00. Following the completion of the transaction, the executive vice president now directly owns 44,088 shares of the company’s stock, valued at $4,215,694.56. The disclosure for this sale can be found here. Insiders sold a total of 30,940 shares of company stock valued at $2,873,126 in the last three months. 1.75% of the stock is currently owned by corporate insiders.

Institutional Trading of BioMarin Pharmaceutical

Institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC lifted its position in BioMarin Pharmaceutical by 188.6% in the second quarter. Quadrant Capital Group LLC now owns 355 shares of the biotechnology company’s stock worth $29,000 after buying an additional 232 shares during the last quarter. Acadian Asset Management LLC lifted its position in BioMarin Pharmaceutical by 395.4% in the first quarter. Acadian Asset Management LLC now owns 431 shares of the biotechnology company’s stock worth $32,000 after buying an additional 344 shares during the last quarter. Capital Wealth Alliance LLC bought a new stake in BioMarin Pharmaceutical in the second quarter worth $34,000. CWM LLC lifted its position in BioMarin Pharmaceutical by 435.2% in the first quarter. CWM LLC now owns 487 shares of the biotechnology company’s stock worth $38,000 after buying an additional 396 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its position in shares of BioMarin Pharmaceutical by 1,014.6% during the second quarter. First Horizon Advisors Inc. now owns 535 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 487 shares during the last quarter. 94.84% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Price Performance

BMRN opened at $88.21 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.69 and a current ratio of 5.42. The stock has a market capitalization of $16.36 billion, a P/E ratio of 339.28, a P/E/G ratio of 1.90 and a beta of 0.32. The company’s 50-day simple moving average is $90.06 and its two-hundred day simple moving average is $83.31. BioMarin Pharmaceutical has a 52-week low of $70.73 and a 52-week high of $97.76.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.04. BioMarin Pharmaceutical had a net margin of 2.83% and a return on equity of 1.78%. During the same quarter in the previous year, the company posted $0.23 EPS. As a group, analysts predict that BioMarin Pharmaceutical will post 0.91 EPS for the current year.

About BioMarin Pharmaceutical

(Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.